XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa January 25, 2019/0 Comments/in Hidradenitis suppurativa /by SteveIntravenous administration of bermekimab showed compelling phase II data in hidradenitis suppurativa (HS). Bermekimab beat adalimumab … Source link Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window) Related https://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.png 0 0 Steve https://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.png Steve2019-01-25 02:27:362019-01-25 02:27:36XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa
Leave a Reply
Want to join the discussion?Feel free to contribute!